Skip to main navigation
Akero
  • Contact
  • Linked
  • Twitter
  • About
    • Our Company
    • Our History
    • Leadership
    • Contact
  • Focus
    • Therapeutic Areas
    • Publications & Posters
  • Pipeline
    • Development Pipeline
    • Efruxifermin (EFX)
    • Research Programs
  • Clinical Trials
    • Clinical Trials Overview
    • Expanded Access Policy
  • Careers
    • Our Culture
    • Job Opportunities
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • Contact IR
Select Page
Akero
    • About
      • Our Company
      • Our History
      • Leadership
      • Contact
    • Focus
      • Therapeutic Areas
      • Publications & Posters
    • Pipeline
      • Development Pipeline
      • Efruxifermin (EFX)
      • Research Programs
    • Clinical Trials
      • Clinical Trials Overview
      • Expanded Access Policy
    • Careers
      • Our Culture
      • Job Opportunities
    • Investors & Media
      • Corporate Profile
      • Press Releases
      • Events & Presentations
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Historic Price Lookup
        • Analyst Coverage
      • SEC Filings
      • Corporate Governance
        • Documents & Charters
        • Management Team
        • Board of Directors
        • Committee Composition
      • Investor Resources
        • Investor FAQs
        • Investor Email Alerts
        • Contact IR
    • Linked
    • Twitter
Hero-banner

SEC Filing Details

Hero-banner

Document Details

Form
SC 13G/A
Filing Date
Feb 14, 2022
Document Date
Feb 14, 2022
Form Description
An amendment to the SC 13G filing
Filing Group
Other
Company
Akero Therapeutics, Inc.
Issuer
Akero Therapeutics, Inc.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
  • About
  • Our Company
  • Our History
  • Leadership
  • Contact
  • Focus
  • Therapeutic Areas
  • Publications & Posters
  • Pipeline
  • Development Pipeline
  • Efruxifermin (EFX)
  • Research Programs
  • Clinical Trials
  • Clinical Trials Overview
  • Expanded Access Policy
  • Careers
  • Our Culture
  • Job Opportunities
  • Investors & Media
  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investor Resources
Footer logo
©2021 Akero Therapeutics, Inc.
  • Privacy Policy
  • Terms of Use
  • Linked
  • Twitter